Zyphar's Pharmaceutics Private Limited

Zyphar's Pharmaceutics Private Limited, incorporated on February 17, 2006, is a privately held Indian pharmaceutical company headquartered in Pune, Maharashtra. The company is registered under the Corporate Identification Number (CIN) U24231PN2006PTC022042. Its authorized and paid-up capital stands at ₹4.95 crore (approximately $660,000 USD). The registered office is located at Office No. 102 & 103, Park Plaza, First Floor, Opp Kamala Nehru Park, Erandwane, Pune, Maharashtra 411004, India.

Zyphar's Pharmaceutics specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio is concentrated in two therapeutic categories: Advanced Oncology (64.1%) and Biologics & Immunotherapy (35.9%). The top three exported products are Procarbazine ($13K, Rank #5, 3.5% market share), Adalimumab ($9K, Rank #8, 0.8% market share), and Lomustine ($3K, Rank #7, 3.2% market share). The total export value amounts to $26K USD across 31 shipments, indicating a focused export strategy.

Zyphar's Pharmaceutics operates manufacturing facilities in Pune, Maharashtra. While specific details regarding plant capacities and specializations are not publicly disclosed, the company's focus on oncology and biologics suggests that its facilities are equipped to handle the production of complex formulations in these therapeutic areas.

The leadership team of Zyphar's Pharmaceutics comprises:

• Mahendra Champalal Jain
• Rajeshkumar Champalal Jain
• Roshan Champalal Jain
• Kapil Ganeshmal Sonigara

All directors were appointed on February 17, 2006. Specific roles and responsibilities within the company are not detailed in the available sources.

Zyphar's Pharmaceutics has a limited presence in highly regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan. The company's export data indicates a focus on specific products without evidence of widespread regulatory approvals or market access in these regions. This suggests that the company may not have pursued or achieved significant market penetration in these territories.

The company's export activities are primarily concentrated in Advanced Oncology and Biologics & Immunotherapy, therapeutic areas with significant demand in emerging markets. However, there is no specific information regarding Zyphar's Pharmaceutics' penetration in Africa, Latin America, or Southeast Asia. The absence of WHO prequalification or similar certifications indicates that the company may not have pursued these markets actively.

Zyphar's Pharmaceutics exhibits a concentrated geographic strategy, focusing on a limited number of products without diversification into multiple markets. This approach may mitigate risks associated with market entry but also limits potential revenue streams from a broader geographic footprint.

There is no publicly available information indicating that Zyphar's Pharmaceutics has FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or a history of FDA inspections. This suggests that the company may not have pursued or achieved FDA approvals for its products.

The available data does not confirm that Zyphar's Pharmaceutics holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. This absence may limit the company's ability to access certain international markets that require such certifications.

Zyphar's Pharmaceutics is registered with the Central Drugs Standard Control Organisation (CDSCO) in India, as indicated by its Corporate Identification Number (CIN) U24231PN2006PTC022042. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs) are not publicly available.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts issued to Zyphar's Pharmaceutics. This suggests that the company has not faced significant regulatory actions in the public domain.

Zyphar's Pharmaceutics operates in the competitive pharmaceutical industry, focusing on oncology and biologics. While specific competitors are not identified in the available data, the company's concentrated product portfolio and limited market presence may position it as a niche player in these therapeutic areas.

Zyphar's Pharmaceutics' focus on high-quality, cost-effective life-saving products in oncology and immunotherapy sets it apart. The company's commitment to delivering "Made in India" formulations matching global standards reflects its dedication to quality and international competitiveness.

Zyphar's Pharmaceutics appears to be strategically positioned as a manufacturer of specialized pharmaceutical formulations, particularly in oncology and biologics. The company's future outlook may involve expanding its product portfolio and pursuing regulatory approvals to access broader international markets.

Zyphar's Pharmaceutics has demonstrated consistency in its export activities, with a total export value of $26K USD across 31 shipments. The company's focus on a limited number of products suggests a specialized approach to manufacturing and supply. However, the absence of certifications such as WHO prequalification or EU GMP may impact its reliability indicators in certain markets.

Importers should verify the following certifications before engaging with Zyphar's Pharmaceutics:

• FDA Facility Registration: To confirm compliance with U.S. regulatory standards.
• WHO Prequalification: To assess eligibility for international procurement programs.
• EU GMP Certificate: To ensure adherence to European manufacturing standards.

Verification can be conducted through the respective regulatory bodies' official websites or by direct communication with the company.

Before engaging with Zyphar's Pharmaceutics, consider the following steps:

• Verify Regulatory Certifications: Confirm the presence of FDA, WHO, and EU certifications.
• Assess Manufacturing Capabilities: Evaluate the company's facilities and production capacities.
• Review Financial Health: Analyze financial statements for profitability and stability.
• Check Export Records: Review export history for consistency and reliability.
• Conduct Site Visits: If possible, visit manufacturing sites to assess compliance and quality standards.

Be cautious of red flags such as lack of certifications, inconsistent financial records, or negative regulatory history.